<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="Activity\PMC7829935\results\search\disease\results.xml">
  <result pre="Î²-amino acid moiety-containing heterocycles presenting antiviral, anti-inflammatory, antibacterial compounds, anaplastic" exact="lymphoma" post="kinase (ALK) inhibitors, as well as agonist and antagonists"/>
  <result pre="demonstrated that these types of compounds present antiproliferative activities on" exact="glioma" post="cell lines (C6 rat and U-138-MG human) [12]. Î²-Amino"/>
  <result pre="compounds exhibiting antiviral properties. Some known structures act against the" exact="influenza" post="virus [15]. Neuraminidase, a glycoprotein expressed on the influenza"/>
  <result pre="the influenza virus [15]. Neuraminidase, a glycoprotein expressed on the" exact="influenza" post="virusâ€™ surface, is crucial for virus replication and infectivity"/>
  <result pre="motifs also has found application in searching for new anaplastic" exact="lymphoma" post="kinase (ALK) inhibitors for the treatment of nonâ€&quot;small-cell lung"/>
  <result pre="anaplastic lymphoma kinase (ALK) inhibitors for the treatment of nonâ€&quot;small-cell" exact="lung cancer" post="(NSCLC) [26]. Although there are known heterocycles as well"/>
  <result pre="lymphoma kinase (ALK) inhibitors for the treatment of nonâ€&quot;small-cell lung" exact="cancer" post="(NSCLC) [26]. Although there are known heterocycles as well"/>
  <result pre="appropriate bioavailability of drugs for treating a broad spectrum of" exact="influenza" post="viruses, including seasonal flu and possible pandemic infections. All"/>
  <result pre="influenza viruses, including seasonal flu and possible pandemic infections. All" exact="influenza" post="viruses bear two surface glycoproteins, hemagglutinin and neuraminidase, which"/>
  <result pre="and neuraminidase, which are the antigens that define the particular" exact="influenza" post="strain. The hemagglutinin is a sialic acid receptorâ€&quot;binding molecule"/>
  <result pre="as zanamivir and oseltamivir [28]. However, a mutation of the" exact="influenza" post="virus resulted in its resistance to these drugs, which"/>
  <result pre="of neuraminidase inhibitors containing a Î²-amino acid moiety for the" exact="influenza" post="virus. Wang et al. [29] started from the initial"/>
  <result pre="a Î²-amino acid moiety. Some substrates mimic the inhibitors of" exact="influenza" post="virus neuraminidase, for example, the thioglycoside, 3-deoxy-3-fluoro derivative and"/>
  <result pre="in cell cultures) with HSV-1, Mayaro virus, and VSV (vesicular" exact="stomatitis" post="virus) to calculate the selective or therapeutic index of"/>
  <result pre="an unsaturated Î²-amino acid moiety, showed 100% inhibition against Mycobacterium" exact="tuberculosis" post="and also presented strong antibacterial activity against 24 pathogenic"/>
  <result pre="and labor. Additionally, the well-known protective effect of aspirin on" exact="colon cancer" post="may be through the way it affects COX-2, which"/>
  <result pre="labor. Additionally, the well-known protective effect of aspirin on colon" exact="cancer" post="may be through the way it affects COX-2, which"/>
  <result pre="(PGH2), a committed step in prostanoid synthesis. In patients with" exact="rheumatoid arthritis" post="or osteoarthritis, tolmetin inhibited disease activity similarly to aspirin"/>
  <result pre="a committed step in prostanoid synthesis. In patients with rheumatoid" exact="arthritis" post="or osteoarthritis, tolmetin inhibited disease activity similarly to aspirin"/>
  <result pre="risk of gastrointestinal bleeding, risk of renal failure, compromised hemostasis," exact="hypersensitivity" post="to aspirin or other NSAIDs, labor, delivery, and nursing"/>
  <result pre="airborne respiratory tract pathogen that typically causes prolonged, dry cough," exact="pharyngitis" post="and, hoarseness, often accompanied by sinusitis (approximately 70% of"/>
  <result pre="causes prolonged, dry cough, pharyngitis and, hoarseness, often accompanied by" exact="sinusitis" post="(approximately 70% of acute C. pneumoniae respiratory tract infections)."/>
  <result pre="tract infections). Additionally, it is estimated that 5â€&quot;10% of community-acquired" exact="pneumonia" post="cases are caused by C. pneumoniae, and elderly patients"/>
  <result pre="acid moiety, which are used in the treatment of community-acquired" exact="pneumonia" post="caused by Chlamydia pneumoniae and chronic prostatitis caused by"/>
  <result pre="treatment of community-acquired pneumonia caused by Chlamydia pneumoniae and chronic" exact="prostatitis" post="caused by Chlamydia trachomatis, respectively [54,55]. Oxetin (Table 4,"/>
  <result pre="acts as a serine protease inhibitor. 2.4. ALK Inhibitors Non-small-cell" exact="lung cancer" post="(NSCLC) is the leading cause of cancer-related deaths worldwide."/>
  <result pre="as a serine protease inhibitor. 2.4. ALK Inhibitors Non-small-cell lung" exact="cancer" post="(NSCLC) is the leading cause of cancer-related deaths worldwide."/>
  <result pre="modest improvements in overall survival. Researchers from Japan identified anaplastic" exact="lymphoma" post="kinase (ALK) as another potential target in NSCLC. ALK-positive"/>
  <result pre="kinase (ALK) as another potential target in NSCLC. ALK-positive (anaplastic" exact="lymphoma" post="kinase positive, or ALK+) lung cancer occurs in 1"/>
  <result pre="target in NSCLC. ALK-positive (anaplastic lymphoma kinase positive, or ALK+)" exact="lung cancer" post="occurs in 1 out of 25 non-small-cell lung cancer"/>
  <result pre="in NSCLC. ALK-positive (anaplastic lymphoma kinase positive, or ALK+) lung" exact="cancer" post="occurs in 1 out of 25 non-small-cell lung cancer"/>
  <result pre="ALK+) lung cancer occurs in 1 out of 25 non-small-cell" exact="lung cancer" post="patients. Generally, patients under 55 years of age who"/>
  <result pre="lung cancer occurs in 1 out of 25 non-small-cell lung" exact="cancer" post="patients. Generally, patients under 55 years of age who"/>
  <result pre="causes such cells to grow abnormally, and ultimately, behave as" exact="cancer" post="cells. ALK inhibitors are anticancer drugs that affect tumors"/>
  <result pre="anticancer drugs that affect tumors with variations of the anaplastic" exact="lymphoma" post="kinase, such as an EML-ALK translocation [26,73]. Since crizotinib"/>
  <result pre="The drug regulates the work of the heart and prevents" exact="atrial fibrillation" post="[77]. Patients undergoing cardiovascular surgery have an increased risk"/>
  <result pre="perioperative myocardial ischemic injury. Additionally, noncardiovascular surgeries involving patients with" exact="cardiovascular disease" post="risk factors also carry an increased incidence of mortality"/>
  <result pre="Lett.20162661361710.1016/j.bmcl.2015.11.06326646219 12.TreptowT.G.FigueirÃ³F.JandreyE.H.BattastiniA.M.SalbegoC.G.HoppeJ.B.TabordaP.S.RosaS.B.PiovesanL.A.Dâ€™OcaC.D.R.M.et al.Novel hybrid DHPM-fatty acids: Synthesis and activity against" exact="glioma" post="cell growth in vitroEur. J. Med. Chem.20159555256210.1016/j.ejmech.2015.03.06225863023 13.PatockaJ.Î²-Amino acids"/>
  <result pre="ValleL.KhaliliK.Evidence for involvement of Wnt signaling pathway in IB-MECA mediated" exact="suppression" post="of melanoma cellsOncogene2002214060406410.1038/sj.onc.120553112037688 21.LiangB.T.JacobsonK.A.A physiological role of the adenosine"/>
  <result pre="Crizotinib and BeyondJ. Cancer Prev. Curr. Res.201781310.15406/jcpcr.2017.08.00275 27.Abdel-MagidA.F.A MaryanoffC.MehrmanS.J.Synthesis of" exact="influenza" post="neuraminidase inhibitorsCurr. Opin. Drug Discov. Dev.20014776791 28.De ClercqE.Antiviral agents"/>
  <result pre="inhibitorsCurr. Opin. Drug Discov. Dev.20014776791 28.De ClercqE.Antiviral agents active against" exact="influenza" post="A virusesNat. Rev. Drug Discov.200651015102510.1038/nrd217517139286 29.WangG.T.ChenY.WangS.GentlesR.SowinT.KatiW.MuchmoreS.GirandaV.StewartK.D.ShamH.et al.Design, synthesis, and"/>
  <result pre="Rev. Drug Discov.200651015102510.1038/nrd217517139286 29.WangG.T.ChenY.WangS.GentlesR.SowinT.KatiW.MuchmoreS.GirandaV.StewartK.D.ShamH.et al.Design, synthesis, and structural analysis of" exact="influenza" post="neuraminidase inhibitors containing pyrrolidine coresJ. Med. Chem.2001441192120110.1021/jm000468c11312919 30.BaiS.LiuS.ZhuY.WuQ.Asymmetric synthesis"/>
  <result pre="Res.20101511211410.1186/2047-783X-15-S2-11221147636 54.HammerschlagM.R.RoblinP.M.Microbiologic efficacy of moxifloxacin for the treatment of community-acquired" exact="pneumonia" post="due to Chlamydia pneumoniaeInt. J. Antimicrob. Agents20001514915210.1016/S0924-8579(00)00157-610854812 55.LepejS.Å½idovec Comparative"/>
  <result pre="analysis of azithromycin and ciprofloxacin in the treatment of chronic" exact="prostatitis" post="caused by Chlamydia trachomatisInt. J. Antimicrob. Agents20032145746210.1016/s0924-8579(03)00056-612727080 56.KawahataY.TakatsutoS.IkekawaN.MurataM.OmuraS.Synthesis of"/>
  <result pre="74.LatifM.AshrafZ.BasitS.GhaffarA.ZafarM.S.SaeedA.MeoS.A.Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic" exact="lymphoma" post="kinase inhibitors: Discovery and clinical developmentsRSC Adv.20188164701649310.1039/C8RA01934G 75.ShiW.LiJ.-Y.GSK1838705a, an"/>
  <result pre="76.SabbatiniP.KorenchukS.RowandJ.L.GroyA.LiuQ.LeperiD.AtkinsC.DumbleM.YangJ.AndersonK.et al.GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic" exact="lymphoma" post="kinase and shows antitumor activity in experimental models of"/>
  <result pre="adenovirus type 7 strains Compound 9 Anti-HIV activity,inhibitor of Mycobacterium" exact="tuberculosis" post="Compound 10 Inhibitor of Î—Î&quot;Î½ reverse transcriptase molecules-26-00438-t002_Table 2Table"/>
  <result pre="heterocyclic derivatives with antibacterial activity. Compound 18Moxifloxacin Activity against Chlamydia" exact="pneumonia" post="Compound 19Ciprofloxacin Activity againstChlamydia trachomatis Compound 20Oxetin Inhibits Bacillus"/>
 </snippets>
</snippetsTree>
